APOE and Alzheimer disease: Further, the possible presence of older carriers of the APOE ε4 allele with preclinical, undiagnosed AD in the broad age range of middle-aged participants (40–65 years) might confound separation of possible protective effects of APOE on cognition from prodromal AD.